Clinical use of triptans in the management of migraine;Utilisation clinique des triptans dans la prise en charge de la migraine

CNS Drugs

Volumn 20, Issue SUPPL. 1, 2006, Pages 12-23

  Lantéri Minet, Michel ^a  

^a PASTEUR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; ELETRIPTAN; ERGOTAMINE DERIVATIVE; FROVATRIPTAN; MACROLIDE; MONOAMINE OXIDASE INHIBITOR; NARATRIPTAN; PROPRANOLOL; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ACUTE DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; HUMAN; META ANALYSIS; MIGRAINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS; DRUG EVALUATION; HUMANS; MIGRAINE DISORDERS; SEROTONIN AGENTS; TRYPTAMINES;

EID: 33645512200     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. 1B/1D receptor agonists in migraine: comparative pharmacology and its therapeutic implications. CNS Drugs 1998; 10: 271-86
2. Humphrey PPA, Goadsby PJ. Controversies in headache. The mode of action of sumatriptan is vascular. Cephalalgia 1994; 14: 401-10
3. Olesen J. Do we really understand how the triptans work? In: The Triptans. Novel Drugs for Migraine. P Humphrey, M Ferrari, J Olesen (eds). Frontiers in Headache Research. Oxford: Oxford University Press. 2001. pp. 152-7
4. Dahlof CG. Integrating the triptans into clinical practice. Curr Opin Neurol 2002; 15: 317-22
5. Feniuk W, Humphrey PPA. The importance of vasoconstriction in the mechanism of the antimigraine action of the triptans. In: The Triptans. Novel Drugs for Migraine. P Humphrey, M Ferrari, J Olesen (eds). Frontiers in Headache Research. Oxford: Oxford University Press. 2001. pp. 125-33
6. Milson D. Clinical pharmacokinetics of the triptans: what are the important clinical issues? In: The Triptans. Novel Drugs for Migraine. P Humphrey, M Ferrari, J Olesen (eds). Frontiers in Headache Research. Oxford: Oxford University Press. 2001. pp. 57-71
7. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999; 19: 115-27
8. 1B/1D agonists) in acute treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668-75
9. Oldman AD, Smith LA, McQuay HJ, et al. Pharmacological treatments for acute migraine: quantitive systematic review. Pain 2002; 97: 247-57
10. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharamcokinetics and efficacy. Drugs 2000; 60: 1259-87
11. Lucas C, Lantéri-Minet M, Auray JP, et al. Migraine in France in 2000: therapeutical data. In: The Triptans. Novel Drugs for Migraine. P Humphrey,MFerrari, J Olesen (eds). Frontiers in Headache Research. Oxford: Oxford University Press. 2001. pp. 309-13
12. Lucas C, Chaffaut C, Artaz MA, et al. FRAMIG 2000: Medical and therapeutic management of migraine in France. Cephalalgia 2005; 25: 267-79
13. Ryan R, Géraud G, Goldstein J, et al. Clinical efficacy frovatriptan: placebo-controlled studies. Headache 2002; (Suppl 2): 84-92
14. Charlesworth BR, Dowson AJ, Purdy A, et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine. CNS Drugs 2003; 17: 653-67
15. Tfelt-Hansen P, Block G, Dahlof CG, et al. Guidelines controlled trials of drugs in migraine. Cephalalgia 2000;765-86
16. Davies GM, Santanello N, Lipton RB. Determinants of satisfaction with migraine therapy. Cephalalgia 2000; 20: 554-60
17. Saxena PR, Tfelt-Hansen P. Triptans, 5-HT1B/1D receptor agonists in the acute treatment of migraine. In: The Headaches, Second Edition. J Olesen, P Tfelt-Hansen, KMA Welch (eds). Lippincott Williams and Wilkins, Philadelphia. 2000; pp. 411-38
18. Dahlof CG. Characteristics of different routes of administration. In: The Triptans. Novel Drugs for Migraine. P Humphrey, M Ferrari, J Olesen (eds). Frontiers in Headache Research. Oxford: Oxford University Press. 2001. pp. 80-90
19. Dahlof C. Assessing patient preference in migraine treatment. Cephalalgia 2001; 21: 791-5
20. Cady RK, Lipton RB, Hall C, et al. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 2000; 40: 792-7
21. Cady RK, Sheftell F, Lipton RB, et al. Effect of early treatment with sumatriptan on migraine pain: retrospective analyses data from three clinical trials. Clin Ther 2000; 22: 1035-48
22. Scholpp J, Schellenberg R, Moeckesch B, et al. Early intervention of a migraine attack while pain is still mild increases efficacy of sumatriptan. Cephalalgia 2004; 24: 925-33
23. Klapper J, Lucas C, Rosjo O, et al; ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia 2004; 24: 918-24
24. Pascual J. Clinical benefits of early triptan for migraine. Headache 2002; 42 (Suppl 1): 10-7
25. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against development of cutaneous allodynia. Ann Neurol 2004; 55: 19-26
26. Luciani R, Carter D, Mannix L, et al. Prevention of migraine during prodrome with naratriptan. Cephalalgia 2000;122-6
27. Weiller C, May A, Limmorth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;658-60
28. Desnuelle M, Fabre N, Payoux P, et al. Brainstem and hypothalamic activation in spontaneous attacks: a PET study. Cephalalgia 2004; 24: 782
29. Visser WH, Jaspers NM, de Vriend RH, et al. Risk factors headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996; 16: 264-9
30. Teall J, Tuchman M, Cutler N, et al. Rizatriptan 022 Study Group. Rizatriptan for the acute treatment of migraine and migraine recurrence. Headache 1998; 38: 281-7
31. Aurora SK. Headache recurrence as a criterion for assessing efficacy of triptans: a perspective. Headache 2002; 42: 70-9
32. Visser WH, Burgraaff J, Muller LM, et al. Pharmacokinetics and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 1996; 60: 452-60
33. Ferrari MD. How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. Cephalalgia 1999; 23: 2-4
34. Tfelt-Hansen P, Saxena PR, Dahlof CG, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 2000; 123: 9-18
35. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. Rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 2001; 22: 309-12
36. Hargreaves R, Beer M. 5-HT receptors in brain and vasculature. In: The Triptans. Novel Drugs for Migraine. P Humphrey, M Ferrari, J Olesen (eds). Frontiers in Headache Research. Oxford: Oxford University Press. 2001. pp.11-22
37. 2 receptor activation. Eur J Pharmacol 1989; 161: 91-4
38. Maassen VanDenBrink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98: 25-30
39. Welch KMA, Mathew NT, Stone P, et al. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000; 20: 687-95
40. Knudsen JF, Friedman B, Chen M, et al. Ischemic colitis and sumatriptan use. Arch Intern Med 1998; 158: 1946-8
41. Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache 2002; 42 (Suppl 2): 93-9
42. Dodick DW, Martin V. Triptans and CNS side-effects: pharmacokinetics and metabolic mechanisms. Cephalalgia 2004; 24: 417-24
43. Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalagia 1996; 16: 323-7
44. Lantéri-Minet M. Les céphalées par abus médicamenteux. Pathol Biol 2000; 48: 707-14
45. Abu-Shakra S, Yates R. Pharamacokinetics and tolerability of repeated oral doses of zolmitriptan in adults. Neurology 2002; 58 (Suppl 3): 291
46. Lanteri-Minet M, Alchaar H, Coullet P, et al. Overuse of new 5-HT agonists (zolmitriptan, naratriptan) in migraine patients: clinical features. In: The Triptans. Novel Drugs for Migraine. P Humphrey, M Ferrari, J Olesen (eds). Frontiers in Headache Research. Oxford: Oxford University Press. 2001. pp. 331-4
47. Gaist D. Use and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data. Cephalalgia 1999; 19: 753-61
48. Lanteri-Minet M, Auray JP, El Hasnaoui A, et al. Prevalence and description of chronic daily headache in the general population in France. Pain 2003; 102: 143-9
49. Limmroth V, Katsarava Z, Fritsche F, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59: 1011-4
50. Katsarava Z, Fritsche G, Muessig M, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57: 1694-8
51. Geraud G, Lanteri-Minet M, Lucas C, et al. on behalf of the French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004; 26: 1305-18
52. Becker WJ. Are the triptans for migraine therapy worth the cost? Can J Neurol Sci 2000; 27: 111-5
53. Vuillaume De Diego E, Lanteri-Minet M. Recognition and management of migraine in primary care: influence of functional impact measured by the headache impact test (HIT). Cephalalgia 2005; 25: 184-90
54. Lipton RB, Stewart WF, Stone AM, et al. Stratified care vs step care strategies for migraine: the Disability In Strategies of Care (DISC) Study: a randomized trial. JAMA 2000; 284: 2599-605
55. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during migraine aura. Neurology 1994; 44: 1587-92
56. 1D agonist prevent migraine headache when taken during an aura?. Eur Neurol 1996; 36 (Suppl 2): 28-31
57. Olesen J, Diener HC, Schoenen J, et al. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004; 11: 671-7
58. Lewis D, Ashwal S, Hershey A, et al. Pratice parameter: pharmacological treatment of migraine headache in children and adolescents. Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004; 63: 2215-24
59. Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs 2003; 17: 1-7
60. Strak S, Spierings EL, McNeal S, et al. Naratriptan efficacy in migrainers who respond poorly to oral sumatriptan. Headache 2000; 40: 513-20